Patients diagnosed with hereditary cancer syndromes (HCS) mutations are at increased risk of developing tumors. We are trying to evaluate the utility and cost-effectiveness of WB MRI for screening and monitoring adult HCS patients for new lesions (malignant or pre malignant). We retrospectively collected the data from the HCS patients who had whole-body MRI scans and are aged 18 -72 years old. Overall sensitivity and specificity of WB MRI is 100% and 87.5% and mean per patient cost responsibility per scan is $358.83 which proves WB MRI can be an effective tool for screening and surveillance of HCS patients.
This abstract and the presentation materials are available to members only; a login is required.